Success Metrics

Active Trials
3(50%)

Phase Distribution

Ph phase_2
4
67%
Ph early_phase_1
1
17%
Ph phase_3
1
17%

Phase Distribution

1

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Terminated(2)
Other(1)

Detailed Status

Recruiting3
Withdrawn2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (16.7%)
Phase 24 (66.7%)
Phase 31 (16.7%)

Trials by Status

unknown117%
withdrawn233%
recruiting350%

Recent Activity

3 active trials
Showing 5 of 6
recruitingphase_3

Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.

NCT05387603
recruitingphase_2

"Receptor Radionuclide Therapy With 177Lu-DOTATOC

NCT06045260
recruitingearly_phase_1

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

NCT05359146
withdrawnphase_2

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

NCT04276597
withdrawnphase_2

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

NCT04915144
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05387603Phase 3

Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.

Recruiting
NCT06045260Phase 2

"Receptor Radionuclide Therapy With 177Lu-DOTATOC

Recruiting
NCT05359146Early Phase 1

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

Recruiting
NCT04276597Phase 2

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

Withdrawn
NCT04915144Phase 2

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Withdrawn
NCT04194125Phase 2

Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6